Insights

Australia approves Pfizer vaccine for kids aged 12-15 years old

The Therapeutics Goods Administration decided to approve the vaccine for kids late last night.
The post Australia approves Pfizer vaccine for kids aged 12-15 years old appeared first on The Motley Fool Australia. –

The Pfizer Inc. (NYSE: PFE) COVID-19 vaccine has been approved for use in children aged 12-15 years in Australia.

The Therapeutics Goods Administration (TGA) made the decision late last night. Previously, COVID vaccines were only approved for those over the age of 16.

The TGA said in a statement:

“(Approval) has been made following careful evaluation of the available data supporting safety and efficacy, including clinical studies with adolescents 12 to 15 years of age.”

The highly infectious delta variant is spreading in Australia, including in children. This is unlike previous strains, so today’s news will provide options for worried parents.

However, the TGA says:

“Continued approval depends on the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.”

Pfizer replaces AstraZeneca as vaccine du jour

Australia is ranked last for the percentage of people fully vaccinated in the Organisation for Economic Co-operation and Development (OECD), and second last for people who have just one dose of the vaccine.

https://ourworldindata.org/covid-vaccinations

The federal government was relying on the bulk of supply to come from locally CSL Limited (ASX: CSL) manufactured AstraZeneca plc (LON: AZN).

However, emerging evidence of an extremely rare blood clotting disorder caused by the vaccine led to the government’s expert advisory body, ATAGI, to recommend only those aged over 50, later 60, should take the vaccine.

Large swathes of Australians, including older residents, are reluctant to take the vaccine. Instead, they are waiting for more Pfizer vaccine.

The problem is we have too much AstraZeneca and not enough Pfizer vaccine.

The government acted to double the supply of Pfizer, as well as order Moderna Inc (NASDAQ: MRNA) vaccine as well. The bulk of this additional supply will arrive in the fourth quarter of this year.

The federal government has indemnified GPs who administer AstraZeneca in an attempt to get more jabs in arms.

It is available to those under 40 years who choose to take the jab at their doctor’s office.

While today’s news is positive, there is no expectation that children will be able to get inoculated any time soon.

Federal Health Minister, Greg Hunt said:

“Our plans are in place to roll out what is more likely, on the early advice I have, is that they will fast-track vaccines for 12- to 15-year-olds for the immunocompromised children or those with underlying health conditions,” Hunt told Channel 7.

Other children will need to wait, along with adults, for more supply of Pfizer most likely in September or October.

The post Australia approves Pfizer vaccine for kids aged 12-15 years old appeared first on The Motley Fool Australia.

Our TOP healthcare stock is trading at a 15% discount to its highs

If there’s one thing for sure, 2020 was the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.

Better yet, this fast-growing company is currently trading at a 15% discount from its highs. Scott believes in this stock so much, he’s staked $209k of our own company money on it. Forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.

Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!

As of 15.02.2021

More reading

Why Moderna topped the market on Thursday

2 blue chip ASX 200 shares rated as buys

What is the outlook for the CSL (ASX:CSL) share price?
I’m investing for my kids. Any advice?

Polynovo (ASX:PNV) share price bounces off 10-month lows, up 3% today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!